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Abstract
Background: Type 2 diabetes mellitus (T2DM) and obesity have become two of the main threats to public health in the
Western world. In addition, obesity is the most important determinant of the sleep apnea-hypopnea syndrome (SAHS), a
condition that adversely affects glucose metabolism. However, it is unknown whether patients with diabetes have more
severe SAHS than non-diabetic subjects. The aim of this cross-sectional case-control study was to evaluate whether obese
patients with T2DM are more prone to severe SAHS than obese non-diabetic subjects.
Methodology/Principal Findings: Thirty obese T2DM and 60 non-diabetic women closely matched by age, body mass
index, waist circumference, and smoking status were recruited from the outpatient Obesity Unit of a university hospital. The
exclusion criteria included chronic respiratory disease, smoking habit, neuromuscular and cerebrovascular disease, alcohol
abuse, use of sedatives, and pregnancy. Examinations included a non-attended respiratory polygraphy, pulmonary function
testing, and an awake arterial gasometry. Oxygen saturation measures included the percentage of time spent at saturations
below 90% (CT90). A high prevalence of SAHS was found in both groups (T2DM:80%, nondiabetic:78.3%). No differences in
the number of sleep apnea-hypopnea events between diabetic and non-diabetic patients were observed. However, in
diabetic patients, a significantly increase in the CT90 was detected (20.2630.2% vs. 6.8613,5%; p=0.027). In addition,
residual volume (RV) was significantly higher in T2DM (percentage of predicted: 79.7618.1 vs. 100.1622.8; p,0.001).
Multiple linear regression analyses showed that T2DM but not RV was independently associated with CT90.
Conclusions/Significance: T2DM adversely affects breathing during sleep, becoming an independent risk factor for severe
nocturnal hypoxemia in obese patients. Given that SAHS is a risk factor of cardiovascular disease, the screening for SAHS in
T2DM patients seems mandatory.
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Introduction
Sleep apnea-hypopnea syndrome (SAHS) has been well
established as an independent risk factor for hypertension,
myocardial infarction, and stroke [1]. Obesity is the most
important determinant of SAHS with more than 50% of patients
having a BMI higher that 30 kg/m
2 [2]. In recent years,
increasing evidence has appeared suggesting an association
between SAHS and type 2 diabetes mellitus (T2DM), two
common disorders that occur with increased frequency in the
obese population [3]. The available data suggest that long-term
exposure to intermittent hypoxia and sleep fragmentation
increases sympathetic nerve activity, contributing to disorders of
glucose metabolism [4]. In this regard, a high prevalence of fasting
hyperglucemia, insulin resistance, and T2DM has been found
among SAHS patients in comparison with healthy subjects [5].
Alternatively, some studies propose that insulin resistance and
chronic hyperglycemia might contribute to the development of
SAHS. Vgontzas et al [6] found that women with polycystic ovary
syndrome, a condition associated with insulin resistance, were
much more likely than controls to have SAHS and daytime
sleepiness, suggesting that insulin resistance is a mediator of SAHS
in humans. Additionally, an analysis of the Sleep Heart Health Study
found that subjects with clinically diagnosed T2DM had increased
sleep-disordered breathing and more severe sleep hypoxemia,
although after correcting for the main factors involved in the
development of SAHS the difference in sleep hypoxemia was
eliminated [7]. Finally, in non-obese rats, Ramadan et al [8] have
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resistance in the development of apneic episodes, and how
treatment with metformin, a drug currently used to raise insulin
sensitivity, reversed and prevented these episodes. However, it is
unknown whether or not diabetic patients have more severe
apneic episodes than non-diabetic patients.
On this basis, the aim of this case-control study was to evaluate
the prevalence and characteristics of SAHS according to the
presence of T2DM. For this purpose, polygraphy and respiratory
function data were compared between diabetic and non-diabetic
patients closely matched by the most important variables that
could affect the prevalence and severity of sleep-disordered
breathing.
Materials and Methods
Ethic statement
Informed written consent was obtained from all participants,
and the human ethics committee from the Hospital Universitari
Vall d’Hebro ´n approved the study.
Description of patients
A total of thirty consecutive morbidly obese type 2 diabetic
women attending the outpatient Obesity Unit of a university
hospital were recruited for the study over a 18-months period. The
main clinical features are displayed in table 1. Sixty non-diabetic
women attending the same Obesity Unit served as control group.
Both groups were carefully matched by age, BMI, and waist
circumference.
A complete physical examination was performed with special
attention to neurological, cardiopulmonary, and ear, nose and
throat evaluations. The exclusion criteria were: chronic respiratory
disease, smoking habit, clinical history of neuromuscular disease,
narcolepsy, stroke, transient ischemic attack, chronic heart failure,
craniofacial abnormalities, abuse of alcohol or use of sedatives,
pregnancy, and endocrinological diseases apart from obesity and
diabetes mellitus. T2DM was defined according to the criteria
recommended by the Expert Committee on the Diagnosis and
Classification of Diabetes [9]. The degree of sleepiness was
evaluated using the Epworth Sleepiness Scale (ESS), a widely used
questionnaire based on the tendency to fall asleep during various
daytime situations [10].
Measurement of sleep disorders of breathing and
respiratory function data
A previously validated non-attended respiratory polygraphy was
performed at patients’ homes with a Somnea polygraph
(Compumedics, Abbotsford, Australia) which records nasal airflow
(nasal cannula), respiratory effort (chest and abdominal bands),
snoring, body position and finger pulse oxymetry [11]. After the
performance of the study patients were required to answer a
questionnaire on self-perception of sleep quality, subjective
number of hours slept and number of awakenings. An expert
scorer blinded to the study reviewed all sleep studies manually.
Studies with less than 5 hours of correct signal recording were
ruled out and repeated. An apnea was defined as cessation of
airflow with duration of at least 10 seconds. Differentiation was
made between obstructive and central apneas according to the
respiratory effort channels (presence or absence of thoracoabdom-
inal movements). Hypopnea was defined as a .50% reduction in
nasal cannula tracing with a duration of at least 10 seconds
associated with a cyclical dip in arterial oxygen saturation (SaO2)
$3%. The apnea-hypopnea index (AHI) was defined as the sum of
apneas plus hypopneas divided by time in bed. On this basis,
SAHS was defined as an AHI$10 events/hour, and patients were
divided into non-SAHS (AHI,10 events/hour), mild SAHS (AHI
between 10 and 20 events/hour), moderate SAHS (AHI between
21 and 29 events/hour), and severe SAHS (AHI .30 events/
hour). Three oxygen saturation measures were assessed: the
cumulative percentage of time spent with oxygen saturations
below 90% (CT90), and the lowest and the average SaO2.
Forced spirometry and static pulmonary volume measurements
were performed using a MasterLab apparatus (MasterLab; Jaeger;
Wu ¨rzburg, Germany). All tests were performed following
European Respiratory Society guidelines [12]. Static pulmonary
volumes were measured using the plethysmography method. The
theoretical values proposed by Roca et al [13] were applied for
spirometry, and values proposed by the European Respiratory
Society for static volumes [12].
Room air arterial blood gas sampling was performed according
to standard guidelines. Briefly, after patients had been sitting for at
least 10 minutes samples were anaerobically drawn into prehepar-
inized syringes following the administration of local anesthesia in
the area of the radial artery. Air bubbles were removed and each
sample was taken immediately for analysis using an IL 682 co-
oxymeter (Instrumentation Laboratories, Lexington; MA).
Statistical analysis
Normal distribution of the variables was evaluated using the
Kolmogorov-Smirnov test. Data were expressed either as the
mean (SD) or percentage. Given their skewed distribution, AHI
and oxygen saturation data were expressed as median (range). For
parametric tests, AHI was logarithmically transformed to achieve a
normal distribution. Comparisons between groups were per-
formed using Student t tests for continuous variables and the x
2
test for categorical variables. Oxygen saturation data (the lowest
and the average SaO2) were compared using non-parametric tests
(Mann-Whitney U test). The relationship between the continuous
variables was examined by the Pearson linear correlation test.
A stepwise multiple linear regression analyses to explore the
variables independently related to SAHS severity was performed.
Table 1. Main clinical characteristics of subjects included in
the study.
T2DM Non T2DM P
n (women) 30 60 -
Fasting glucose (mg/dl) 162.43662.93 100.96612.20 ,0.001
HbA1c (%) 7.7061.12 5.9160.36 ,0.001
Total cholesterol (mg/dl) 201.82633.76 204.04643 0.799
LDL cholesterol (mg/dl) 126.86632.04 121.67636.07 0.520
HDL cholesterol (mg/dl) 47.33610.09 49.53618.54 0.570
Triglycerides (mg/dl) 175.78662.70 129.53645.69 ,0.001
Systolic blood pressure
(mmHg)
138.96621.04 138.47621.35 0.923
Diastolic blood pressure
(mmHg)
87.81614.07 92.80611.17 0.088
Insulin treatment, n (%) 6 (20.0) - -
Oral hypoglycemic
agents, n (%)
19 (63.3) - -
Microangyopathy, n (%)
* 4 (13.3) - -
*Non-proliferative retinopathy was present in three patients whereas
microalbuminuria was present in the last one.
doi:10.1371/journal.pone.0004692.t001
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independent variables included in the analyses were: age, BMI,
AHI (log), arterial oxygen pressure (PaO2), arterial carbon dioxide
pressure (PaCO2), residual volume (RV, percentage of predicted),
forced expiratory volume in 1 second to forced vital capacity ratio
(FEV1/FVC), somnolence score, and the presence or absence of
T2DM.
All p values were based on a two-sided test of statistical
significance. Significance was accepted at the level of p,0.05.
Statistical analyses were performed with the SSPS statistical
package (SPSS Inc, Chicago, Illinois).
Results
The main clinical features and pulmonary parameters of the
study population are presented in table 2. A high prevalence of
SAHS, with almost 3 out of 4 subjects affected, was found in both
groups. Diabetic and non-diabetic patients showed a similar
prevalence of mild (37.5% vs. 34.0%), moderate (20.8% vs. 21.3%),
and severe (41.6% vs. 44.6%) SAHS. When polygraphic results
were analysed no significant differences in the number of apnea-
hypopnea events were observed between diabetic and non-diabetic
patients. In addition, the lowest and the average oxygen saturation
levels were also similar in both groups. When the rate (events/
hour) of apneas and hypopneas were evaluated separately, we
observed a similar frequency in diabetic patients than in
nondiabetic patients: 2.8 (0–87.4) vs. 2.8 (0–50.0), p=0.956 for
apneas, and 16.1 (0.7–50.0) vs. 17.0 (0.7–71.4), p=0.969 for
hypopneas. However, diabetic patients spent a significantly higher
percentage of time with oxygen saturation below 90% in
comparison with non-diabetic subjects (20.1%630.2 vs.
6.8%613.5, p=0.027).
Pulmonary function tests showed spirometric and static lung
volumes mean values in the normal range and without significant
differences between the two groups except a greater residual
volume (RV) in diabetic patients, (100.0622.8 vs. 79.7618.1;
p,0.001) (Table 2). Regarding somnolence, an ESS.10 was
present in 6 (20.00%) of the obese women with T2DM and in 8
(13.33%) of the control group (p=0.362)
The univariate analysis showed that CT90 was correlated with
several parameters obtained from non-attended polygraphy and
arterial blood samples including age, AHI(log), average and lowest
SaO2, forced vital capacity (FVC), total lung capacity (TLC),
PaO2, PaCO2, and the ESS (Table 3). However, we did not find
any correlation between CT90 and BMI (r=0.162, p=0.127),
RV (r=0.097, p=0.416) nor FEV1/FVC ratio (r=20.176,
p=0.107).
Multiple linear regression analysis showed that type 2 diabetes
(beta=0.220, p=0.007), together with PaO2 (beta=20.222,
p=0.013), PaCO2 (beta=0.227, p=0.013), AHI(log) (be-
ta=0.387, p,0.001), and the ESS (beta=0.184, p=0.028), were
independently associated with CT90 (R
2=0.582) (table 4).
Table 2. Main clinical features and pulmonary parameters of
subjects included in the study.
T2DM Non T2DM P
n 30 60 -
Age (years) 43.268.0 42.168.0 0.529
BMI (Kg/m
2) 49.166.3 49.166.4 0.989
Waist circumference
(cms)
130.8612.2 129.8613.4 0.746
Polygraphy data:
SAHS, n (%) 24 (80.0) 47 (78.3) 0.855
AHI (events/h) 20.00 (4.90–114.0) 22.70 (0.70–78.0) 0.503
CT90 (%) 20.2630.2 6.8613.5 0.027
Average SaO2 (%) 94.0 (75.0–98.0) 94.0 (88.0–98.0) 0.277
Lowest SaO2 (%) 78.0 (49.0–90.0) 82.0 (49.0–97.0) 0.115
Pulmonary function test:
FVC (%)
* 87.3617.1 89.9613.7 0.447
FEV1 (%)
* 91.2620.2 97.3614.3 0.114
FEV1/FVC (%) 81.469.1 85.065.0 0.058
TLC (%)
* 97.2614.0 94.3611.6 0.369
RV (%)
* 100.1622.8 79.7618.1 ,0.001
Arterial blood samples:
PaO2 (mmHg) 82.3611.4 83.668.1 0.574
PaCO2 (mmHg) 39.765.2 38.963.9 0.441
Epworth Sleepiness Scale 7.364.6 6.564.1 0.453
Data are mean6SD and median (range). T2DM: type 2 diabetes mellitus; BMI:
body mass index; SAHS: sleep apnea-hypopnea syndrome; AHI: apnea-
hipoapnea index; CT90: percentage of time spent with oxygen saturations
below 90%; SaO2: arterial oxygen saturation; FVC: forced vital capacity; FEV1:
forced expiratory volume in 1 second; TLC: total lung capacity; RV: residual
volume; PaO2: arterial oxygen pressure; PaCO2: arterial carbon dioxide pressure.
*Value expressed as a percentage of the predicted value.
doi:10.1371/journal.pone.0004692.t002
Table 3. Correlations of percentage of time spent with
oxygen saturations below 90% (CT90) with clinical and
metabolic variables obtained in the univariate analyses.
Variable r p
Age 0.242 0.022
BMI 0.162 0.127
AHI 0.547 ,0.001
Average SaO2 0.856 ,0.001
Lowest SaO2 20.632 ,0.001
FVC 20.388 ,0.001
FEV1/FVC ratio 20.176 0.107
TLC 20.241 0.040
RV 0.097 0.416
PaO2 20.477 ,0.001
PaCO2 0.475 ,0.001
ESS 0.302 0.005
Fasting glucose 0.097 0.366
HbA1c 0.102 0.549
Systolic blood pressure 0.164 0.143
Diastolic blood pressure 0.195 0.081
Total cholesterol 20.017 0.885
LDL cholesterol 0.009 0.936
HDL cholesterol 20.112 0.335
Triglycerides 0.072 0.537
AHI: apnea-hipoapnea index; SaO2: arterial oxygen saturation; FVC: forced vital
capacity (percentage of predicted); TLC: total lung capacity (percentage of
predicted); RV: residual volume (percentage of predicted); PaO2: arterial oxygen
pressure; PaCO2: arterial carbon dioxide pressure; ESS: Epworth Somnolence
Score.
doi:10.1371/journal.pone.0004692.t003
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To the best of our knowledge, this is the first study to provide
evidence that T2DM is an independent risk factor for severe
nocturnal hypoxemia in morbidly obese patients. In fact, the
cumulative percentage of time spent with oxygen saturation below
90% was three-fold higher in diabetes patients than in non-
diabetic subjects matched by age, gender, BMI and waist
circumference. This is an important finding because sleep related
hypoxia in SAHS patients is known to be a major stimulus leading
to oxidative stress and endothelial dysfunction [14], and may
contribute to the increased risk of fatal and non-fatal cardiovas-
cular events observed in patients with severe SAHS [1]. In our
patients, this effect may be an additional source of oxidative stress
to that associated with T2DM [15]. Therefore, due to its high
prevalence and severity it seems mandatory to investigate SAHS,
and in particular nocturnal hypoxemia, in this subset of diabetic
subjects.
As previously described, sleep hypoxemia in our patients was
related to awake blood gases and AHI [16]. The deleterious effect
of the presence of T2DM on CT90 in obese SAHS patients
observed in our study may be mediated through several
mechanisms. It has been suggested that insulin resistance, through
both the activation of nuclear factor kappa B by increased levels of
cytokines (i.e., IL-6 and TNF-alpha) and the releasing of free fatty
acids by excess adipose tissue, is involved in the pathogenic
mechanisms leading to SAHS in humans [17]. Data supporting
this hypothesis include the significant reduction of sleepiness and
sleep apnea/hypopnea events in obese patients after the
administration of etanercept, a TNF-alpha antagonist [18]. In
addition, Ramadan et al [8] demonstrated that insulin resistance
was one of the primary mechanism leading to sleep apnea in rats.
A deleterious effect of diabetes on central respiratory control
attributed to autonomic neuropathy has also been described [19].
Resnick et al [7], using cross-sectional data from the Sleep Heart
Health Study, after adjustment for BMI and other potential
confounders, found that patients with diabetes had more episodes
of periodic breathing, an abnormality of the central control of
ventilation, than did those subjects without diabetes. A limitation
of the study is that the presence of diabetes was based on self-
report or on the use of hypoglycaemic medications. Therefore, it is
possible that a substantial number of individuals were misclassified
as ‘‘non-diabetic’’. However, laboratory based investigations show
that diabetic patients with autonomic neuropathy are more likely
to have not only central, but also obstructive sleep apnea than
diabetic patients without autonomic neuropathy [19]. This
association is also present in non-obese diabetic patients and
seems independent of the severity of their dysautonomy [20]. The
underlying mechanism has to be elucidated, but an impairment of
the upper airway reflexes, possibly due to alterations to the
autonomic nervous fibres involved in their regulation, could lead
to an inability of individuals with diabetes to respond appropri-
ately to sleep apneas. In addition, an impairment of ventilatory
drive associated to leptin resistance has been shown in obese
patients [21]. These mechanisms could lead to a greater instability
of the upper airway and to a more profound hypoxemia observed
in our obese diabetic patients. Furthermore, it has been suggested
that cardiac dysfunction (diminished heart rate variability and left
ventricular dysfunction), common in diabetic neuropathy, may
prolong circulatory time and cause a delay in feedback loops
involving CO2 and O2 central and peripheral chemorreceptors
[7]. Supporting this hypothesis, streptozotocin-induced diabetic
rats exhibited a significant reduction in the ventilatory response to
hypercapnic and hypoxic challenges which was prevented with
insulin treatment [22]. Consequently, our results raise the central
issue of whether the normalization of blood glucose levels in
humans can significantly improve the severity of sleep apnea.
The results obtained in the present study, in which type 2
diabetic subjects showed a significant increase in RV accompanied
with a decrease in the FEV1/FVC ratio, reinforce previous data
[23]. However, it should be noted that our patients had a mean
spirometric and stating lung volume values in the normal range.
We feel that this fact has limited our ability to detect the effect of
pulmonary function test on sleep hypoxemia detected in previous
works. An impairment in pulmonary carbon monoxide diffusing
capacity, which has been reported to be altered in some T2DM
[24], can not be ruled out in our patients. However, we believe
that the magnitude of the impairment previously described would
not explain the sleep hypoxemia found in the present study.
Although it is tempting to suggest a relationship between increased
RV and severe nocturnal hypoxemia in T2DM patients with
SAHS, no correlation between RV and data obtained from the
non-attended polygraphy, including CT90, was observed. These
findings strongly suggest that the higher severity of SAHS observed
in T2DM was unrelated to pulmonary function tests.
There are some potential limitations that should be taken into
account in evaluating the results of our study. First, this was a
cross-sectional study and, therefore, a causal link between T2DM
and sleep hypoxemia can not be drawn. In this regard, studies
addressed to determining whether the normalization of blood
glucose levels could improve SAHS events or hypoxia are
warranted. Second, patients were not matched for neck circum-
ference. However, it has been described that visceral fat is the
main risk factor for SAHS in obese subjects, whereas the AHI does
not correlate with subcutaneous fat in the neck or parapharingeal
regions [25]. Third, we have considered a selected population of
morbidly obese women and, consequently, further studies in non-
obese T2D patients are required.
In conclusion, T2DM adversely affects breathing abnormalities
during sleep in morbid obese patients. Given that SAHS is a risk
factor of cardiovascular disease, the screening for SAHS in these
patients seems mandatory. Further studies to define not only the
mechanisms through which T2DM promotes severe hypoxemia in
SAHS but also to determine whether or not blood glucose control
could arrest or prevent this deleterious effect are needed.
Table 4. Multiple linear regression analysis of variables
associated with the percentage of time spent with oxygen
saturations below 90% (CT90).
Beta p
AHI (log) 0.387 ,0.001
PaCO2 (mmHg) 0.227 0.013
T2DM (yes/no) 0.220 0.007
PaO2 (mmHg) 20.222 0.013
BMI (Kg/m
2) 20.094 0.279
ESS 0.184 0.028
Age (yrs) 20.001 0.859
R
2 0.582
Beta: Standardized partial regression coefficient. AHI: apnea-hypopnea index;
PaCO2: arterial carbon dioxide pressure; T2DM: type 2 diabetes mellitus; PaO2:
arterial oxygen pressure; BMI: body mass index; ESS: Epworth Sleepiness Scale;
RV: residual volume (percentage of predicted); FEV1/FVC: forced expiratory
volume in 1 second to forced vital capacity ratio.
doi:10.1371/journal.pone.0004692.t004
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